Systemic hormone therapy and dementia: A nested case-control and co-twin control study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Systemic hormone therapy and dementia : A nested case-control and co-twin control study. / Lokkegaard, Laura Ekstrom; Thinggaard, Mikael; Nygaard, Marianne; Hallas, Jesper; Osler, Merete; Christensen, Kaare.
I: Maturitas, Bind 165, 2022, s. 113-119.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Systemic hormone therapy and dementia
T2 - A nested case-control and co-twin control study
AU - Lokkegaard, Laura Ekstrom
AU - Thinggaard, Mikael
AU - Nygaard, Marianne
AU - Hallas, Jesper
AU - Osler, Merete
AU - Christensen, Kaare
PY - 2022
Y1 - 2022
N2 - Objective: The effect of systemic hormone therapy (HT) on dementia risk is unclear. Our aim was to investigate the association between HT and dementia.Study design: This register-based study consists of a nested case-control study and a co-twin control design, which controls for familial confounding, including shared genetics.Main outcome measures: Through Danish national registries from 1995 to 2011, we identified: a) 2700 female singletons with incident dementia and 13,492 matched controls; b) 288 female twins with incident dementia and co-twins without dementia. Data on HT and education were retrieved, and analyses were performed using conditional logistic regression and McNemar's chi(2)-test. HT use decreased dramatically after the Women's Health Initiative study results were published in 2002, and the analyses were stratified accordingly to account for potentially different HT user characteristics.Results: The odds ratio (OR) for the association between systemic HT and dementia was 1.05, 95% CI = [0.93-1.19] in singletons and 2.10, 95% CI = [0.99-4.46] in twins. A statistically significant association was found for systemic HT before 2003 in both populations, with an OR of 1.14, 95% CI = [1.01-1.28] in singletons and an OR of 2.20, 95% CI = [1.04-4.65] in twins.Conclusion: Using Danish nationwide registries and controlling for education and for familial factors in a subsample, systemic HT was found to be associated with increased dementia risk if used before 2003, when HT was more commonly prescribed.
AB - Objective: The effect of systemic hormone therapy (HT) on dementia risk is unclear. Our aim was to investigate the association between HT and dementia.Study design: This register-based study consists of a nested case-control study and a co-twin control design, which controls for familial confounding, including shared genetics.Main outcome measures: Through Danish national registries from 1995 to 2011, we identified: a) 2700 female singletons with incident dementia and 13,492 matched controls; b) 288 female twins with incident dementia and co-twins without dementia. Data on HT and education were retrieved, and analyses were performed using conditional logistic regression and McNemar's chi(2)-test. HT use decreased dramatically after the Women's Health Initiative study results were published in 2002, and the analyses were stratified accordingly to account for potentially different HT user characteristics.Results: The odds ratio (OR) for the association between systemic HT and dementia was 1.05, 95% CI = [0.93-1.19] in singletons and 2.10, 95% CI = [0.99-4.46] in twins. A statistically significant association was found for systemic HT before 2003 in both populations, with an OR of 1.14, 95% CI = [1.01-1.28] in singletons and an OR of 2.20, 95% CI = [1.04-4.65] in twins.Conclusion: Using Danish nationwide registries and controlling for education and for familial factors in a subsample, systemic HT was found to be associated with increased dementia risk if used before 2003, when HT was more commonly prescribed.
KW - Postmenopausal hormone therapy
KW - Twins
KW - Register data
KW - Population-based study
KW - MILD COGNITIVE IMPAIRMENT
KW - HEALTH INITIATIVE MEMORY
KW - REPLACEMENT THERAPY
KW - POSTMENOPAUSAL WOMEN
KW - ALZHEIMERS-DISEASE
KW - ALL-CAUSE
KW - RISK
KW - PREVENTION
KW - MORTALITY
KW - DENMARK
U2 - 10.1016/j.maturitas.2022.04.007
DO - 10.1016/j.maturitas.2022.04.007
M3 - Journal article
C2 - 36184115
VL - 165
SP - 113
EP - 119
JO - Maturitas
JF - Maturitas
SN - 0378-5122
ER -
ID: 345511366